Intangible Assets

SAGE’s moat from intangible assets is mainly tied to FDA-approved neuroscience assets and clinical know-how, which can support pricing power versus generic biotech peers but is narrower than platform-heavy peers with broader approved franchises.

The company’s value is concentrated in a small number of proprietary programs, so durability depends on continued regulatory and clinical success rather than a diversified patent estate like larger specialty pharma peers.

Compared with diversified biopharma peers, SAGE has less brand breadth and fewer marketed products, which limits the persistence of intangible-asset-driven retention and pricing leverage over 5–10 years.

The absence of broad recurring commercial brands means intangible assets are meaningful but not yet strong enough to create peer-leading structural advantage.

Switching Costs

SAGE has limited switching costs because its products are not embedded in long-duration enterprise workflows or chronic-care systems that would make customers materially dependent on the company versus peers.

In neuroscience therapeutics, prescribers and payers can shift usage toward alternative therapies as clinical data, reimbursement, or safety profiles change, which weakens retention versus more entrenched pharma franchises.

Unlike peers with large hospital formularies or device ecosystems, SAGE does not appear to benefit from contractual lock-in that would preserve pricing power after launch.

Any switching friction is mostly clinical and reimbursement-based rather than structural, so it is weaker than peers with broader approved portfolios and established treatment pathways.

Network Effects

SAGE does not exhibit meaningful network effects because demand for its therapies does not become more valuable as more users join the platform, unlike software or marketplace peers.

Clinical adoption can improve with physician familiarity and evidence generation, but that is not a self-reinforcing network effect that materially compounds moat strength versus peers.

There is no clear ecosystem loop in which third-party developers, users, or partners increase the product’s value in a way that creates durable peer-dependent advantage.

Relative to peers with data-network or platform dynamics, SAGE’s competitive position is not reinforced by network-driven retention or pricing power.

Cost Advantage

SAGE’s negative ROIC and ROCE indicate that it is not currently converting capital into returns more efficiently than peers, which argues against a durable cost advantage.

The company’s small scale likely prevents the manufacturing, SG&A, and procurement leverage seen at larger specialty pharma peers, limiting margin resilience.

Its very low asset turnover suggests a capital-light commercial model has not yet translated into superior operating efficiency versus peers.

Any cost advantage is not evident in the current financial profile, so pricing power and margin durability remain weaker than for larger, scaled competitors.

Efficient Scale

SAGE may benefit from some efficient-scale characteristics in narrow neuroscience niches because the market can support only a limited number of specialized players, which can reduce direct peer intensity.

However, the presence of multiple large biopharma and specialty pharma alternatives means the company does not control a market structure that would materially deter entry or preserve excess returns.

Compared with dominant rare-disease or orphan-drug peers, SAGE’s scale is too small to create a durable capacity or distribution bottleneck that protects pricing power.

Efficient scale is therefore present only in a limited sense and does not rise to a strong structural moat.

Overall Score

SAGE’s moat is modest and mainly rests on narrow intangible assets from proprietary neuroscience programs, while switching costs, network effects, and cost advantage are weak versus peers; efficient scale exists only in limited niche markets, so overall durability is moderate rather than strong.